Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schizophrenia Drugs And Diabetes: VA Data On Causal Link Expected In June

Executive Summary

The Department of Veterans Affairs expects to have data from a study on the relationship between atypical antipsychotics and diabetes in late June

You may also be interested in...



VA Antipsychotic Diabetes Risk Studies Continue; First Report Helps Zyprexa

The Department of Veteran's Affairs plans to conduct a study on the incidence of diabetes among patients receiving combination antipsychotic therapy as a follow up to its study of patients on monotherapy

VA Antipsychotic Diabetes Risk Studies Continue; First Report Helps Zyprexa

The Department of Veteran's Affairs plans to conduct a study on the incidence of diabetes among patients receiving combination antipsychotic therapy as a follow up to its study of patients on monotherapy

VA study of antipsychotic-related diabetes

Department of Veteran's Affairs study "Antipsychotic Induced Diabetes in Veteran Schizophrenic Patients" will be submitted to the Journal of the American Medical Association for publication at the beginning of September (1"The Pink Sheet" April 21, 2003, p. 11). The study, scheduled to be presented at the International Conference on Therapeutic Risk in Philadelphia Aug. 24, found that Lilly's Zyprexa, Johnson & Johnson's Risperdal and AstraZeneca's Seroquel are associated with similar rates of metabolic complications...

Related Content

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel